Progress and challenges for the machine learning-based design of fit-for-purpose monoclonal antibodies
Although the therapeutic efficacy and commercial success of monoclonal antibodies (mAbs)
are tremendous, the design and discovery of new candidates remain a time and cost …
are tremendous, the design and discovery of new candidates remain a time and cost …
Assessing developability early in the discovery process for novel biologics
Beyond potency, a good developability profile is a key attribute of a biological drug.
Selecting and screening for such attributes early in the drug development process can save …
Selecting and screening for such attributes early in the drug development process can save …
Machine learning prediction of antibody aggregation and viscosity for high concentration formulation development of protein therapeutics
Machine learning has been recently used to predict therapeutic antibody aggregation rates
and viscosity at high concentrations (150 mg/ml). These works focused on commercially …
and viscosity at high concentrations (150 mg/ml). These works focused on commercially …
Contextualising the developability risk of antibodies with lambda light chains using enhanced therapeutic antibody profiling
Antibodies with lambda light chains (λ-antibodies) are generally considered to be less
developable than those with kappa light chains (κ-antibodies). Though this hypothesis has …
developable than those with kappa light chains (κ-antibodies). Though this hypothesis has …
Understanding AL amyloidosis with a little help from in vivo models
G Martinez-Rivas, S Bender, C Sirac - Frontiers in Immunology, 2022 - frontiersin.org
Monoclonal immunoglobulin (Ig) light chain amyloidosis (AL) is a rare but severe disease
that may occur when a B or plasma cell clone secretes an excess of free Ig light chains …
that may occur when a B or plasma cell clone secretes an excess of free Ig light chains …
Machine learning approaches in diagnosis, prognosis and treatment selection of cardiac amyloidosis
Cardiac amyloidosis is an uncommon restrictive cardiomyopathy featuring an unregulated
amyloid protein deposition that impairs organic function. Early cardiac amyloidosis …
amyloid protein deposition that impairs organic function. Early cardiac amyloidosis …
Role of the mechanisms for antibody repertoire diversification in monoclonal light chain deposition disorders: when a friend becomes foe
L Del Pozo-Yauner, GA Herrera… - Frontiers in …, 2023 - frontiersin.org
The adaptive immune system of jawed vertebrates generates a highly diverse repertoire of
antibodies to meet the antigenic challenges of a constantly evolving biological ecosystem …
antibodies to meet the antigenic challenges of a constantly evolving biological ecosystem …
AB-Amy: machine learning aided amyloidogenic risk prediction of therapeutic antibody light chains
Y Zhou, Z Huang, Y Gou, S Liu, W Yang… - Antibody …, 2023 - academic.oup.com
Over 120 FDA-approved antibody-based therapeutics are used to treat a variety of diseases.
However, many candidates could fail because of unfavorable physicochemical properties …
However, many candidates could fail because of unfavorable physicochemical properties …
Widespread amyloidogenicity potential of multiple myeloma patient-derived immunoglobulin light chains
R Sternke-Hoffmann, T Pauly, RK Norrild, J Hansen… - BMC biology, 2023 - Springer
Background In a range of human disorders such as multiple myeloma (MM),
immunoglobulin light chains (IgLCs) can be produced at very high concentrations. This can …
immunoglobulin light chains (IgLCs) can be produced at very high concentrations. This can …
[PDF][PDF] AbPROP: language and graph deep learning for antibody property prediction
T Widatalla, ZA Rollins, MT Chen… - ICML workshop on …, 2023 - icml-compbio.github.io
Despite the rising importance of monoclonal antibodies as clinical therapeutics, sizes of
experimental datasets for antibody developability remain in the 100's, creating a challenge …
experimental datasets for antibody developability remain in the 100's, creating a challenge …